Let’s start up with the current stock price of Matinas BioPharma Holdings Inc. (MTNB), which is $0.79 to be very precise. The Stock rose vividly during the last session to $0.78 after opening rate of $0.78 while the lowest price it went was recorded $0.76 before closing at $0.78.
Recently in News on November 20, 2020, Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients. Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that it has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF). The award will support preclinical development of MAT2501, Matinas’ lipid nano-crystal (LNC) oral formulation of the broad-spectrum aminoglycoside amikacin, toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF). You can read further details here
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Matinas BioPharma Holdings Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.3900 on 01/02/20, with the lowest value was $0.4900 for the same time period, recorded on 04/07/20.
Matinas BioPharma Holdings Inc. (MTNB) full year performance was -36.92%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Matinas BioPharma Holdings Inc. shares are logging -68.10% during the 52-week period from high price, and 62.08% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.49 and $2.49.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1065356 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Matinas BioPharma Holdings Inc. (MTNB) recorded performance in the market was -65.82%, having the revenues showcasing -6.77% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 154.99M, as it employees total of 21 workers.
The Analysts eye on Matinas BioPharma Holdings Inc. (MTNB)
During the last month, 4 analysts gave the Matinas BioPharma Holdings Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.8104, with a change in the price was noted +0.0277. In a similar fashion, Matinas BioPharma Holdings Inc. posted a movement of +3.54% for the period of last 100 days, recording 2,174,071 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for MTNB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Matinas BioPharma Holdings Inc. (MTNB)
Raw Stochastic average of Matinas BioPharma Holdings Inc. in the period of last 50 days is set at 50.39%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 44.39%. In the last 20 days, the company’s Stochastic %K was 32.13% and its Stochastic %D was recorded 24.58%.
Considering, the past performance of Matinas BioPharma Holdings Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -65.82%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -12.82%, alongside a downfall of -36.92% for the period of the last 12 months. The shares increased approximately by -3.61% in the 7-day charts and went up by -7.60% in the period of the last 30 days. Common stock shares were lifted by -6.77% during last recorded quarter.